Join Dr. Maya Khalil, renowned Hematology-Oncologist from Kirklin Clinic of UAB Hospital and Assistant Professor at the University of Alabama at Birmingham, as she delves into the intricate realm of RET+ NSCLC. In this exclusive segment from the 2022 Targeted Therapies Forum, Dr. Khalil demystifies the processes behind detecting RET mutations and offers insights into the typical profiles of patients who carry these mutations.
A big shoutout to our prestigious sponsors: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech for backing this endeavor.
Hungry for more cutting-edge discussions and breakthroughs in the field of oncology? Make sure to explore http://cancerGRACE.org/. Connect and engage with top oncologists and patient advocates at https://cancergrace.org/forum.